Cytonics Corporation
Cytonics is a biotechnology research and development company specializing in developing diagnostics and therapeutics for osteoarthritis and other musculoskeletal diseases. Their mission is to eradicate osteoarthritis pain and improve quality of life through innovative biologic therapies. They have developed products such as the FACT diagnostic test, the autologous A2M therapy (APIC™), and are pursuing pre-clinical studies for their lead recombinant A2M candidate, Cyt-108. Supported by partnerships with leading research institutions and funding from NIH and industry investors, Cytonics aims to revolutionize regenerative medicine for joint and cartilage health.
Industries
Nr. of Employees
small (1-50)
Cytonics Corporation
Products
Autologous A2M concentrate (blood-derived A2M preparation)
A clinical preparation produced by concentrating alpha-2-macroglobulin from a patient’s plasma via a PRP-based workflow and filtration to generate an injectable A2M-rich composition for intra-articular or soft-tissue use.
Recombinant alpha-2-macroglobulin therapeutic candidate
A recombinant variant of human alpha-2-macroglobulin engineered to modify functional regions to increase protease-inhibitory potency; advanced through expression, purification, and in vitro protease-inhibition testing toward IND-enabling studies.
Biomarker diagnostic assay for joint and spine-related pain (FAC biomarker assay)
An assay detecting a fibronectin-aggrecan complex in synovial or disc fluid to assist clinicians in identifying symptomatic joints or discs and informing treatment selection.
Patent portfolio
Granted and pending patents covering concentrated A2M compositions, recombinant A2M variants, plasma-processing systems and methods, and methods of treatment for musculoskeletal conditions and chronic wounds.
Autologous A2M concentrate (blood-derived A2M preparation)
A clinical preparation produced by concentrating alpha-2-macroglobulin from a patient’s plasma via a PRP-based workflow and filtration to generate an injectable A2M-rich composition for intra-articular or soft-tissue use.
Recombinant alpha-2-macroglobulin therapeutic candidate
A recombinant variant of human alpha-2-macroglobulin engineered to modify functional regions to increase protease-inhibitory potency; advanced through expression, purification, and in vitro protease-inhibition testing toward IND-enabling studies.
Biomarker diagnostic assay for joint and spine-related pain (FAC biomarker assay)
An assay detecting a fibronectin-aggrecan complex in synovial or disc fluid to assist clinicians in identifying symptomatic joints or discs and informing treatment selection.
Patent portfolio
Granted and pending patents covering concentrated A2M compositions, recombinant A2M variants, plasma-processing systems and methods, and methods of treatment for musculoskeletal conditions and chronic wounds.
Services
Sponsored research and academic collaborations
Design and management of sponsored studies with academic and clinical partners to validate biomarkers and investigate therapeutic mechanisms.
Licensing and commercialization
Negotiation and execution of licensing agreements and exclusive sublicenses for processing systems and autologous therapies, including veterinary market licensing.
CRO-managed preclinical and IND-enabling study coordination
Commissioning and coordination of external contract research organizations for pilot, toxicology, and large-animal studies to generate IND-enabling datasets.
Sponsored research and academic collaborations
Design and management of sponsored studies with academic and clinical partners to validate biomarkers and investigate therapeutic mechanisms.
Licensing and commercialization
Negotiation and execution of licensing agreements and exclusive sublicenses for processing systems and autologous therapies, including veterinary market licensing.
CRO-managed preclinical and IND-enabling study coordination
Commissioning and coordination of external contract research organizations for pilot, toxicology, and large-animal studies to generate IND-enabling datasets.
Expertise Areas
- Biologic therapeutic development (recombinant and autologous)
- Biomarker discovery and diagnostic assay development for musculoskeletal conditions
- Preclinical translational studies and large-animal osteoarthritis models
- Recombinant protein expression and purification process development
Key Technologies
- Recombinant protein expression and purification
- Autologous plasma fractionation and PRP concentration
- Biomarker assay for fibronectin-aggrecan complex
- Protease-inhibition biochemical and enzymatic assays